Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9432428 | 1.00 | KMT2A (0.47) | KMT2AACP3PTGS1PTGS2KDM5A | |
| SCHEMBL3682275 | 0.89 | KMT2A (0.53) | KMT2APTGS1PTGS2MEN1LMNA | |
| SCHEMBL9136495 | 0.84 | MMP8 (0.44) | ACP3 | |
| SCHEMBL12707192 | 0.84 | KMT2A (0.48) | KMT2AACP3PTGS1PTGS2MEN1 | |
| SCHEMBL29484096 | 0.82 | PTGS1 (0.62) | KMT2AACP3PTGS1PTGS2MEN1 | |
| SCHEMBL1653533 | 0.82 | PTGS1 (0.62) | KMT2AACP3PTGS1PTGS2MEN1 | |
| SCHEMBL1492817 | 0.82 | PTGS1 (0.62) | KMT2AACP3PTGS1PTGS2MEN1 | |
| SCHEMBL5285167 | 0.82 | HIF1A (0.49) | KMT2APTGS1PTGS2MEN1LMNA | |
| SCHEMBL9158042 | 0.82 | KMT2A (0.47) | KMT2APTGS1PTGS2MEN1HSD17B10 | |
| SCHEMBL9158035 | 0.82 | KMT2A (0.47) | KMT2APTGS1PTGS2MEN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118218027-A | Application of polydentate ligand/ruthenium catalyst and method for preparing diol compound by hydrogenation reaction of alpha-hydroxy ester | 郑州大学 | 2024-06-21 | — | — | CN | claimed |
| CN-118218027-A | Application of polydentate ligand/ruthenium catalyst and method for preparing diol compound by hydrogenation reaction of alpha-hydroxy ester | 郑州大学 | 2024-06-21 | — | — | CN | disclosed |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-1550662-B1 | ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| EP-0422597-B1 | Derivatives of phenylacetic acid and fungicides containing them | BASF AG (DE) | 1996-07-24 | — | — | EP | disclosed |
| US-5286750-A | For crops or ornamental plants | BASF AKTIENGESELLSCHAFT (DE) | 1994-02-15 | — | — | US | disclosed |
| EP-0422597-A2 | Derivatives of phenylacetic acid and fungicides containing them | BASF Aktiengesellschaft (DE) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | KMT2A 2009/4885ACP3 4754/4885PTGS1 1141/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | KMT2A 1817/4885ACP3 4780/4885PTGS1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.